Health Care·Pharmaceuticals·$4.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.97 | N/A | +110.87% |
management commentary, guidance changes, and full analysis available with Pro.
| +110.87% |
Tone: Cautiously Optimistic
Overall, management conveyed a sense of optimism regarding the company's performance. However, they did not provide specific guidance for future quarters.
Management expressed satisfaction with the EPS results despite not providing revenue figures.
They highlighted ongoing projects and potential future developments.
Ligand Pharmaceuticals reported a strong EPS performance, significantly exceeding expectations, which led to a modest increase in stock price. The lack of revenue data and guidance may leave investors cautious, but the positive EPS surprise suggests underlying strength in the company's operations. The stock's slight uptick reflects investor confidence in the reported results.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SYSCO CORP
May 2, 2016